Le Lézard
Classified in: Health
Subject: PER

Lorrie A. Carr Appointed as CEO for Excelera


MINNEAPOLIS, July 16, 2018 /PRNewswire/ -- "After a thorough and deliberate selection process, the Board of Directors is delighted that Lorrie will lead Excelera as we navigate the dynamic and evolving specialty pharmacy industry," said Robert Beacher, Chairman of the Board and interim CEO for Excelera. "Lorrie has a very diverse background within the biopharma and specialty pharmacy sectors, which will allow her to build upon our industry-leading position supporting our Members in caring for complex patients. I have no doubt that she is the right person to lead Excelera into new and innovative growth opportunities."

Prior to joining Excelera, Ms. Carr was the Chief Commercial Officer for ZappRx ? a healthcare technology company whose mission is to alleviate barriers that prevent patient access to life-saving specialty medications. Before ZappRx, Ms. Carr held an executive role within Walgreens Specialty Pharmacy as the Divisional VP of Enterprise Specialty Sales and Product Management. Ms. Carr started her career in the biopharmaceutical industry where she held leadership roles in global market access, reimbursement, managed care, marketing and network development.

"It is my great privilege to have been chosen to lead an innovative specialty healthcare company like Excelera," said Carr. "I am honored to have the opportunity to work with a team of very talented employees and an industry-leading Board of Directors. As CEO, my primary objectives will be to continue the great work that has been started, develop innovative strategies designed to grow and leverage our membership, and build meaningful partnerships with biopharmaceutical clients."

Ms. Carr received her bachelor's degree from Columbia College and holds her MBA from UMASS Isenberg School of Management.

About Excelera 
ExceleraRx Corp. supports the Excelera® Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, enabling member organizations to gain access to limited distribution drugs and restricted payer agreements. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy. For a current list of Excelera specialty pharmacy network members, or for more information about becoming a member of the Excelera network, visit excelerarx.com or follow us on LinkedIn.

 

ExceleraRx Corp. Logo

SOURCE ExceleraRx Corp.


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: